All News

RheumNow Podcast square

Vitamin D Headlines (5.9.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy. 

Read Article
RheumNow Podcast square

Osteoarthritis Risky Business (4.18.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com.  Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.

Read Article
cost.healthcare.jpg

The Increasing Cost of First-Line Biologics for Plaque Psoriasis

Jack Cush, MD

A national commercial claims analysis of first-line use of biologics in biologic−naive plaque psoriasis patients found a near doubling of net treatment costs from 2007 to 2021 ($21 236 to $47 125).

Read Article
RheumNow Podcast square

EMR Messaging Woes (4.11.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com

Read Article
RheumNow Podcast square

An Epidural Letdown (4.4.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Cancer Survival with TNF Inhibitors (3.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
JAK Janus

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Read Article
Single-centre retrospective study, 27 children with refractory juvenile dermatomyositis (jDM) Rx with baricitinib (F/U of 25 mos)-- 77% (21/27) improved skin rashes (62% complete resolution) & Dz activity improved (6 vs 0.8, p<0.01) 70% (19/27) achieved inactive disease https://t.co/rRlhoY9O4q
Dr. John Cush RheumNow ( View Tweet)
Hyperpigmentation in SLE Young complex SLE patient develops blue-grey/slate colored hyperpigmentation on her arms and legs - From? Features Dr. Jack Cush https://t.co/yoKU7rJp8y https://t.co/Kh0tZLJ8SX

Links:

Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Featuring: Dr. Victoria P. Werth Dr. Matilda Nicholas Dr. Anthony Fernandez Dr. Christopher Richardson https://t.co/w7cYVNUI9t
Dr. John Cush RheumNow ( View Tweet)
An emulation trial shows that Humira biosimilars (Amjevita & Imraldi) were equivalent to Humira in psoriasis & achieving PASI <=2, both for new biologic starts and for biologic switchers. https://t.co/8lTGGs2rbP https://t.co/T6rTJ5ESj2

Links:

Dr. John Cush RheumNow ( View Tweet)
Bullhead Sign in #SAPHO Syndrome ▶️Synovitis, ▶️Acne ▶️Pustulosis ▶️Hyperostosis ▶️Osteitis 👉🏽https://t.co/ownI4Q543w via @MayoProceedings https://t.co/FXlTtmsDDX

Links:

Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
✅ Management of #REFRACTORY skin manifestations in patients with #LUPUS ➡️ my practical tips 💪 for #PANLAR2025 🇲🇽 https://t.co/KnJO0eXI4W

Links:

Laurent ARNAUD Lupusreference ( View Tweet)
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Links:

Dr. John Cush RheumNow ( View Tweet)

Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
Dr. John Cush RheumNow ( View Tweet)
Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG

Links:

Dr. John Cush RheumNow ( View Tweet)
Patient info on Sweets Syndrome: acute febrile neutrophilic dermatosis https://t.co/0q93q2NVc9 https://t.co/cE3LA8LaRQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis showed no increased risk of serious infx (SIE) w/ JAK inhibitors use in pts w/ immune-mediated inflammatory skin diseases -- 32 RCTs, 11,917 pts found SIE in 0.62% on JAKi vs 0.51% controls. Meta-analysis found no significant increase in risk of serious infection https://t.co/ugH72nk8bZ
Dr. John Cush RheumNow ( View Tweet)
EMA approved a record 28 biosimilars in 2024 for cancer, osteoporosis, macular degeneration, and immune-related diseases like plaque psoriasis, ulcerative colitis, and Crohn’s disease https://t.co/NNzKRalLvF https://t.co/nfX082a7ON

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×